Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
about
Pharmacotherapy of systemic sclerosisRaynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and managementSystemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Oral sildenafil increases skin hyperaemia induced by iontophoresis of sodium nitroprusside in healthy volunteers.The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trialRecent achievements in the management of Raynaud's phenomenon.Advances in the treatment of Raynaud's phenomenon.Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Management of erectile dysfunction in hypertension: Tips and tricks.Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical TrialsCurrent and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammationVascular involvement in systemic sclerosis (scleroderma).Old medications and new targeted therapies in systemic sclerosis.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsEfficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE studyTreatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot studyDevelopment of a provisional core set of response measures for clinical trials of systemic sclerosis.Fast Cicatrization of Extensive Livedoid Vasculopathy Ulcers under Treatment with Sildenafil.Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenonPhosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions.Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?Optimal management of digital ulcers in systemic sclerosisConsensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.Digital ischemia in scleroderma spectrum of diseases.Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects.Systemic and metabolic effects of PDE5-inhibitor drugsPhosphodiesterase type 5 and cancers: progress and challenges.Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
P2860
Q24629481-2461ACC0-3A2E-41AC-8A45-1DD5A890F833Q28392431-9C11AF2C-2759-41F3-971B-598CC750658CQ31125829-AF81E5FA-2FC0-44E5-AD98-0FA90C96442CQ33621773-26AF114D-FD04-4661-B542-9A5970D115F9Q33724464-D6845C77-E5EF-4EB0-BE6A-B9B00C2832B8Q33797622-57218860-C624-4E0A-8323-78EC45B3C9BFQ33813778-220FFAC6-D1FE-4624-9154-0FA5DEA22823Q33892575-303F3504-E0F7-4782-9D7C-09A9C0B379D2Q34244951-810CB72B-6329-42E5-B99F-8CDA85F30BE5Q34251875-B067FC61-446A-4944-8B22-2A86E7D02B83Q34449909-C6D3B141-05A9-47C4-A431-DC6DB6AF36FFQ35500693-1164C4F5-D3C6-410E-B13A-998F96604419Q35550902-E3FF0BEE-D131-4BF9-92E2-EDD2B3D94FE6Q35557372-BBA80E0F-6FA9-4A0D-884C-0A0A2E9B0F34Q35557424-1FF11FF3-1744-45AC-AD94-045C6083FAB0Q36154430-F85345A5-99F8-4D25-BFB6-CFB172028A2AQ36460566-1418C1BE-9C4B-45E1-8571-F2EDD1FC4ECEQ36968760-9276E4DB-D73C-43FA-82DE-76BC55F6C610Q37152133-F5F1B71A-59E1-49E0-B7CA-A140991E46ECQ37460792-92115BF5-0BB9-40DD-840B-B79A50762D95Q37654012-DD8BEC6B-4C8B-4C2C-BEDE-EA66E79CC25FQ37681576-D52EA3F1-B49B-48E2-B294-E4E24A2A2105Q37724814-9EF43958-41BC-4C4B-9F01-67F3D6B15616Q37848067-A4A0C893-DCCE-4448-91D3-2E79A03AB7D5Q38092636-F9AFB75C-AC76-4610-98F9-62386657BAC1Q38537531-E6D93A91-CF73-404B-8DC9-980848727E8DQ38538817-1538D69A-D3AB-405A-B54A-E5637E486CD3Q39907084-49C42259-338C-4889-A429-389C7880898AQ39951981-62E08AC9-8D90-4B09-A0D2-EA9CBDA83E5FQ40158928-477BEDB5-7D00-4952-8341-734089BEE52DQ41815275-AE2ABB1C-BA1D-42B7-98BF-62F5470590C0Q42129412-0F48F387-1349-47F1-B791-ACC9F46EB8F8Q47171803-39365E81-B655-40B2-AD67-551F6AA3E055Q55247585-17A13256-CE23-4E26-BBAA-ADD53B8049C0
P2860
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
@ast
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
@en
type
label
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
@ast
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
@en
prefLabel
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
@ast
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
@en
P2093
P1433
P1476
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
@en
P2093
Hubertus von Wilmowsky
Kaveh Shariat
Michael Böhm
Roland Fries
P304
P356
10.1161/CIRCULATIONAHA.104.523324
P407
P577
2005-11-01T00:00:00Z